- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03089372
Effect of Repeating Low Intensity Extracorporeal Shock Wave Treatment (LI-ESWT) for Erectile Dysfunction (ED)
Low Intensity Extracorporeal Shock Wave Treatment (LI-ESWT) in Patients With Vasculogenic Erectile Dysfunction (ED): Evaluation of the Efficacy of Re-treatment.
Study Overview
Detailed Description
This is an extension, 2 parallel arms, clinical trial of a previous study in which patients were PDE5I users/responders and were randomized to receive either one or two shockwave treatment sessions per week for a total of 6 weeks, without treatment interval. After completing the 6-month follow up of the first trial , ED patients will be screened, in order to identify if the IIEF ED domain is still abnormal (<26). Afterwards, the 2 groups of the first study will follow the 2 different treatment protocols (once vs twice per week). All patients will receive 6 treatment sessions with Aries, with the same energy level. First treatment session will take place between days 0-28 from the day of the 6-month follow up. All patients will agree and sign a new Informed Consent Form. Therefore, patients who took 6 sessions once a week (Group A in the previous trial) will be switched to take 6 sessions twice a week in 3 weeks, and those already treated with 12 sessions twice a week (Group B in the previous trial) will be treated with 6 sessions once a week.
Study visits and duration
Baseline - Visit: the basic work-up will take place, including medical and sexual history, as well as lab tests, if indicated by medical history. The IIEF-ED domain will be measured, as well as the Sexual Encounter Profile (SEP) for the last 4-week period with at least 4 attempts for intercourse (without PDE5i use). The study criteria will be checked and if patients are eligible (IIEF-ED domain <26), they will receive their first repetitive treatment, either on the same day as the 6-month follow up of the previous study or within maximum 4 weeks.
Treatment Visits: In all treatment visits, patients will receive active LI-ESWT treatment, according to the study protocol. Group A will receive treatment twice per week for three weeks and Group B will receive treatment once per week for six weeks. Interval between 2 treatments will be 7+2days for Group B and 3+1 day for Group A. Adverse events and changes in concomitant medication will be recorded. PDE5i intake is prohibited throughout the treatment period.At visit 6 penile ultrasonography will be conducted in order to check for potential adverse events related to the treatment.
Follow-up visit 1 - 3 (4, 12 and 24 weeks post treatment): the SEP diaries will be returned and the IIEF-ED domain will be completed for the 4 weeks prior to the aforementioned timepoints, during which no PDE5i intake is allowed. The document of the visit (protocol compliance, adverse events) will be completed. At week 12, triplex ultrasonography will be performed by the standard protocol.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Thessaloniki, Greece, 54621
- G.Gennimatas Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Consent to participate
- Age >18
- Presence of vasculogenic erectile dysfunction for at least 6 months
- Positive response to PDE5i
- Patients who completed the 6 months follow-up of a previous study including 6 or 12 sessions of LI-ESWT with Aries device and still have an abnormal IIEF ED domain (< 26)
- Abnormal penile triplex-based hemodynamic parameters (peak flow velocity <35cm/sec)
- Stable heterosexual relationship for more than 3 months
- Sexually active and agree to suspend all ED therapy for the duration of study
Exclusion Criteria:
- Any cause of ED other than vascular related
- Previous radiation therapy to pelvis
- History of radical prostatectomy
- Clinically significant chronic haematological disease
- Cardiovascular conditions that prevent sexual activity
- Peyronie's Disease or penile curvature
- History of heart attack, stroke or any life- threatening arrhythmia within the prior 6 month
- Anti-androgens oral or injectables androgens
- Untreated Hypogonadism as demonstrated by abnormal testosterone levels
- Malignancy within the past 5 years
- Any unstable medical, psychiatric condition or spinal cord injury
- Anatomical or neurological abnormalities in the treatment area
- Use of any treatment for ED within 7 days of screening ( oral medications, vacuum devices, constrictive devices, injections or urethral suppositories)
- Known allergy to ultrasound gel
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group A
Patients will receive two sessions of LI-ESWT per week for a 3 week period (6 sessions totally)
|
The Dornier Aries-ED device will be used for the purpose of the study.
LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).
|
Active Comparator: Group B
Patients will receive one session of LI-ESWT per week for a 6 week period (6 sessions totally)
|
The Dornier Aries-ED device will be used for the purpose of the study.
LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The percent of subjects who achieve clinically important difference (MCID) in the EF domain score of the IIEF
Time Frame: at 6 month follow up visit.
|
MCID is defined according to baseline ED severity as:
|
at 6 month follow up visit.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the EF domain score of the IIEF
Time Frame: baseline and 6 month follow up visit
|
EF domain of the IIEF questionnaire will be completed
|
baseline and 6 month follow up visit
|
Change in Sexual Encounter Profile Question 3 (SEP3) score
Time Frame: baseline and 6 month follow up visit
|
The percent of subjects who answer ''YES'' in question 3 of SEP questionnaire will be reported
|
baseline and 6 month follow up visit
|
Change in mean peak systolic velocity (PSV)
Time Frame: baseline and 3 month follow up visit
|
Mean peak systolic velocity will be measured by penile triplex ultrasonography by the same investigator.
|
baseline and 3 month follow up visit
|
Number of patients with treatment related adverse events
Time Frame: 27 months (Group A) ,30 months (Group B)
|
Potential treatment related adverse events after the first LI-ESWT session and during the 6 month follow up period will be reported
|
27 months (Group A) ,30 months (Group B)
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Clavijo RI, Kohn TP, Kohn JR, Ramasamy R. Effects of Low-Intensity Extracorporeal Shockwave Therapy on Erectile Dysfunction: A Systematic Review and Meta-Analysis. J Sex Med. 2017 Jan;14(1):27-35. doi: 10.1016/j.jsxm.2016.11.001. Epub 2016 Dec 13.
- Vardi Y, Appel B, Jacob G, Massarwi O, Gruenwald I. Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. Eur Urol. 2010 Aug;58(2):243-8. doi: 10.1016/j.eururo.2010.04.004. Epub 2010 May 6.
- Rosen RC, Allen KR, Ni X, Araujo AB. Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. Eur Urol. 2011 Nov;60(5):1010-6. doi: 10.1016/j.eururo.2011.07.053. Epub 2011 Jul 30.
- Lu Z, Lin G, Reed-Maldonado A, Wang C, Lee YC, Lue TF. Low-intensity Extracorporeal Shock Wave Treatment Improves Erectile Function: A Systematic Review and Meta-analysis. Eur Urol. 2017 Feb;71(2):223-233. doi: 10.1016/j.eururo.2016.05.050. Epub 2016 Jun 16.
- Gruenwald I, Kitrey ND, Appel B, Vardi Y. Low-Intensity Extracorporeal Shock Wave Therapy in Vascular Disease and Erectile Dysfunction: Theory and Outcomes. Sex Med Rev. 2013 Jul;1(2):83-90. doi: 10.1002/smrj.9. Epub 2015 Oct 18.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4240/2016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Erectile Dysfunction
-
University of VirginiaActive, not recruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Erectile Dysfunction Due to General Medical Condition | Erectile Dysfunction Due to Arterial InsufficiencyUnited States
-
Cairo UniversityRecruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Simple Prostatectomy | Erectile Dysfunction With Diabetes Mellitus | Erectile Dysfunction Due to Arterial Disease | Erectile Dysfunction Due to Injury | Erectile Dysfunction Due to Neuropathy and other conditionsEgypt
-
University of BaghdadCompletedSexual Dysfunction | Erectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Sexual Abstinence | Erectile Dysfunction With Diabetes Mellitus | Sexual Desire Disorder | Erectile Dysfunction Following Cryotherapy | Erectile Dysfunction... and other conditionsIraq
-
BayerCompletedSexual Dysfunction | Male Erectile DysfunctionBelgium, Italy, France, Germany, Spain, Netherlands, South Africa
-
Cairo UniversityCompletedVasculogenic Erectile DysfunctionEgypt
-
InitiaTerminatedVasculogenic Erectile DysfunctionIsrael
-
InitiaCompletedVasculogenic Erectile DysfunctionIsrael
-
InitiaCompletedVasculogenic Erectile DysfunctionCzech Republic, Lithuania, Netherlands, Palestinian Territories, Occupied
-
Rexahn Pharmaceuticals, Inc.CompletedErectile Dysfunction (ED)United States
-
SK Chemicals Co., Ltd.TerminatedMale Erectile Dysfunction
Clinical Trials on ARIES-ED device
-
Institute for the Study of Urological Diseases,...Completed
-
Institute for the Study of Urological Diseases,...CompletedErectile DysfunctionGreece
-
Institute for the Study of Urological Diseases,...Not yet recruitingChronic Prostatitis With Chronic Pelvic Pain Syndrome
-
Institute for the Study of Urological Diseases,...CompletedChronic ProstatitisGreece
-
University of Nove de JulhoCompletedImpacted Third Molar ToothBrazil
-
Luminex Molecular DiagnosticsCompletedBordetella Infections | Bordetella Pertussis Infection | Bordetella Parapertussis InfectionUnited States, Canada
-
Luminex CorporationCompletedPharyngitis BacterialUnited States
-
Dornier MedTech SystemsCompletedErectile Dysfunction | Sexual Dysfunction, PhysiologicalUnited States
-
Dornier MedTech SystemsTerminatedDornier Aries 2 Extracorporeal Shock Wave Device for the Treatment of Mild Erectile Dysfunction (ED)Erectile DysfunctionUnited States
-
University of PennsylvaniaCompletedObesityUnited States